Navigation path

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport


   Countries

Last Update: 05-09-2013  
Related category(ies):
Health & life sciences  |  Success stories

 

Countries involved in the project described in the article:
Belgium  |  France  |  Germany  |  Netherlands  |  Sweden
Add to PDF "basket"

Personalising deep brain stimulation treatment for Parkinson's disease

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's. Its main symptoms are: shaking, rigidity, slowness of movement and difficulty maintaining an upright posture. More than one million people suffer from the effects of this disease in Europe today, and this is forecast to double by 2030. Economically, the impact is significant: Parkinson's costs Europe an estimated € 14 billion a year.

© freshidea - Fotolia.com

IMPACT is an innovative European Union (EU)-funded research project which aims to improve the quality of life of Parkinson’s disease patients. Its goal is to develop new brain-mapping and brain-stimulation techniques, so they can bring an unprecedented degree of “customisation” to the way each individual patient is treated.

Although there is currently no cure for Parkinson’s disease, its symptoms are treatable. These treatments, however, have serious limitations. Drugs can be used, but they diminish in effectiveness over time and are expensive. Deep Brain Stimulation (DBS) offers a solution when drugs fail. Often described as a “pacemaker for the brain”, DBS works by inserting a probe with tiny electrodes into the brain to deliver mild electric stimuli to restore or improve brain function. But this method is also far from ideal. Still in its infancy, DBS causes significant side-effects in as many as 30% of patients. These side-effects are caused when areas of the brain next to the target area are stimulated unintentionally, and can include speech difficulties, mood swings and blurred vision.

Led by Sapiens Steering Brain Stimulation B.V., a specialised medical device company based in Eindhoven in The Netherlands, the IMPACT project team brings together eight industrial and academic research partners from five European countries. The project team aims to develop a system of imaging and mapping each patient’s brain, to enable personalised optimisation (“tuning”) of DBS therapy in a reliable and efficient manner. In combination with a novel high-resolution DBS probe, the use of dozens of electrodes manufactured with micro-fabrication technology means that the electrical stimulation can be “shaped” precisely to the target area in the brain to deliver the right therapy.

Given that this target area can be just a few millimetres in diameter, and be positioned 10cm down in the brain, the degree of targeting required is highly precise and difficult to achieve. With previous DBS systems, all that was possible after the probe had been inserted was a limited degree of movement up or down, but nothing more precise. If side-effects occurred, adjustment took the form of reducing the power applied to the probe. But while this reduced the area that received the stimulus, it also decreased the beneficial effect on the desired target area.

In the words of Hubert Martens, the Director of Clinical Science and Applications at Sapiens, and one of the company’s co-founders: “Because the stimulation field can be precisely steered, it can be shaped to exactly match the target area. This is something radically new. We expect this will avoid the side-effects of DBS, but without compromising the effectiveness of the treatment,” he explains.

“By using high-quality imaging and high-resolution brain recordings to create a functional map of the brain”, adds Dr Martens, “it is also possible, for the first time, to gather and collate information from the brains of different patients, to overlay them on each other, and use this collective experience to help fine-tune and improve the use of the new Sapiens probe,” he says.

It is expected that the new “personalised” DBS system will also be beneficial for other conditions for which DBS is known to be effective. These include epilepsy, dystonia and Obsessive Compulsive Disorder.

Project details

  • Project acronym: IMPACT
  • Participants: Netherlands (Coordinator), Belgium, France, Germany, Sweden
  • Project FP7 305814
  • Total costs: €6 469 220
  • EU contribution: €4 980 907
  • Duration: September 2012 - August 2016

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site
Project information on CORDIS





  Top   Research Information Center